To evaluate the adverse reactions in the Eloquent 2 trial,<unk>  was combined with lenalidomide and dexamethasone and compared with lenalidomide and dexamethasone alone. The most common adverse reactions (20% or higher) denoted in the<unk>  treated patients in the study were: * Fatigue, diarrhea, pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, and pneumonia Similarly, the adverse reactions in the Eloquent 3 trial were examined by comparing the<unk>  combined with pomalidomide and dexamethasone with the pomalidomide and dexamethasone alone. * Constipation and hyperglycemia
Elotuzumab
Pertuzumab
Idarucizumab
Gatipotuzumab
Theralizumab
Alemtuzumab
Etaracizumab
Risankizumab